Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
CA 2385172 A1 · Owner: Handley, Harold H. · Inventors: Haaparanta, Tapio; Ewalt, Karla L.; Handley, Harold H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A recombinant AB5 B subunit protein including at least one mutation wherein , the mutation alters the number of amino acid residues available for chemical modification as compared to a wild type AB5 B subunit protein and wherein , said recombinant protein retains an effective target ligand bind affinity. For example, specifically designed mutations are produced in the cholera Toxin B subunit (CTB) such that it can still bind with high affinity to its receptor Gm-1, but can be specifically covalently linked at lysines or cysteines to an immunogen or vaccine. The vaccine produced from this coupling is a mucosal vaccine which has high immunogenicity due to the interaction with the CTB. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 5, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 5, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 5, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.